Grufity logoGrufity logo
StocksFundsScreenerSectorsWatchlists
AKYA

AKYA - Akoya Biosciences, Inc. Stock Price, Fair Value and News

5.74USD+0.08 (+1.41%)Market Closed
Watchlist

Market Summary

USD5.74+0.08
Market Closed
1.41%

AKYA Stock Price

View Fullscreen

AKYA RSI Chart

AKYA Valuation

Market Cap

281.7M

Price/Earnings (Trailing)

-3.95

Price/Sales (Trailing)

3.08

EV/EBITDA

-4.73

Price/Free Cashflow

-4.75

AKYA Price/Sales (Trailing)

AKYA Profitability

Operating Margin

56.62%

EBT Margin

-78.10%

Return on Equity

-115.21%

Return on Assets

-40.28%

Free Cashflow Yield

-21.03%

AKYA Fundamentals

AKYA Revenue

Revenue (TTM)

91.4M

Rev. Growth (Yr)

33.75%

Rev. Growth (Qtr)

7.2%

AKYA Earnings

Earnings (TTM)

-71.4M

Earnings Growth (Yr)

27.73%

Earnings Growth (Qtr)

37.91%

Breaking Down AKYA Revenue

Last 7 days

-1.6%

Last 30 days

15.1%

Last 90 days

37.6%

Trailing 12 Months

-48.9%

How does AKYA drawdown profile look like?

AKYA Financial Health

Current Ratio

3.29

Debt/Equity

1.03

Debt/Cashflow

-0.87

AKYA Investor Care

Shares Dilution (1Y)

29.30%

Diluted EPS (TTM)

-2.24

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202379.4M85.0M91.4M0
202259.6M64.4M69.8M74.9M
202143.6M48.1M51.7M54.9M
202000042.4M

Tracking the Latest Insider Buys and Sells of Akoya Biosciences, Inc.

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Dec 19, 2023
mckelligon brian
sold
-33,565
4.4754
-7,500
president and ceo
Dec 19, 2023
mckelligon brian
acquired
2,272
0.303
7,500
president and ceo
Dec 12, 2023
mckelligon brian
sold
-31,871
4.2495
-7,500
president and ceo
Dec 12, 2023
mckelligon brian
acquired
2,272
0.303
7,500
president and ceo
Nov 20, 2023
mckelligon brian
acquired
2,272
0.303
7,500
president and ceo
Nov 20, 2023
mckelligon brian
sold
-32,901
4.3868
-7,500
president and ceo
Nov 06, 2023
kamocsay jennifer
acquired
-
-
30,000
general counsel
Nov 06, 2023
pla frederic
acquired
-
-
30,000
chief operating officer
Sep 07, 2023
pla frederic
bought
92,014
4.60072
20,000
chief operating officer
Jun 12, 2023
mendel scott
bought
100,000
5.00
20,000
-

1–10 of 50

Which funds bought or sold AKYA recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Feb 28, 2024
AMERICAN INTERNATIONAL GROUP, INC.
added
3.49
4,459
56,237
-%
Feb 15, 2024
JANE STREET GROUP, LLC
new
-
107,702
107,702
-%
Feb 15, 2024
Legal & General Group Plc
added
20.89
2,805
13,244
-%
Feb 15, 2024
BARCLAYS PLC
added
512
137,000
163,000
-%
Feb 15, 2024
Farther Finance Advisors, LLC
new
-
20.00
20.00
-%
Feb 14, 2024
BANK OF AMERICA CORP /DE/
added
51.74
39,834
107,073
-%
Feb 14, 2024
DEUTSCHE BANK AG\
added
2,472
102,269
106,203
-%
Feb 14, 2024
AMERIPRISE FINANCIAL INC
reduced
-11.69
-15,440
195,322
-%
Feb 14, 2024
JACOBS LEVY EQUITY MANAGEMENT, INC
sold off
-100
-259,475
-
-%
Feb 14, 2024
KENNEDY CAPITAL MANAGEMENT LLC
sold off
-100
-1,384,600
-
-%

1–10 of 47

Are Funds Buying or Selling AKYA?

Are funds buying AKYA calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own AKYA
No. of Funds

Unveiling Akoya Biosciences, Inc.'s Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2024
telegraph hill partners iii, l.p.
36.0%
17,675,247
SC 13G/A
Feb 12, 2024
psc capital partners llc
7.2%
3,517,360
SC 13G/A
Jan 03, 2024
schindel yair chaim
5.85%
2,871,406
SC 13G/A
Jun 13, 2023
schindel yair chaim
5.16%
2,500,000
SC 13G
Feb 15, 2023
psc capital partners llc
7.2%
2,717,360
SC 13G/A
Feb 14, 2023
psc capital partners llc
7.2%
2,717,360
SC 13G/A
Feb 07, 2023
hudson executive capital lp
4.99%
1,892,204
SC 13D/A
Dec 02, 2022
hudson executive capital lp
6.4%
2,447,558
SC 13D/A
Sep 13, 2022
hudson executive capital lp
9.8%
3,697,558
SC 13D/A
Feb 25, 2022
psc capital partners llc
7.6%
2,813,771
SC 13G

Recent SEC filings of Akoya Biosciences, Inc.

View All Filings
Date Filed Form Type Document
Feb 14, 2024
SC 13G/A
Major Ownership Report
Feb 12, 2024
SC 13G/A
Major Ownership Report
Jan 10, 2024
8-K
Current Report
Jan 08, 2024
8-K
Current Report
Jan 03, 2024
SC 13G/A
Major Ownership Report
Dec 20, 2023
4
Insider Trading
Dec 19, 2023
144
Notice of Insider Sale Intent
Dec 14, 2023
4
Insider Trading
Dec 12, 2023
144
Notice of Insider Sale Intent
Nov 27, 2023
4
Insider Trading

Peers (Alternatives to Akoya Biosciences, Inc.)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
206.3B
40.1B
0.08% 5.41%
36.05
5.14
-8.12% -17.45%
68.0B
19.5B
1.90% -2.48%
54.16
3.49
4.02% -22.04%
22.7B
3.9B
13.67% -2.23%
51
5.88
3.42% 23.09%
20.7B
14.9B
3.05% 1.38%
7.81
1.39
2.01% 209.17%
MID-CAP
9.8B
12.3B
2.56% -12.12%
23.62
0.8
-2.44% -22.68%
9.6B
2.7B
6.89% -27.73%
-15
3.58
-4.68% 82.43%
9.3B
3.5B
8.76% 25.90%
32.61
2.66
4.97% 18.89%
6.8B
4.0B
-8.15% -6.44%
-50.38
1.71
1.10% 85.84%
3.5B
366.4M
-1.40% 20.18%
-569.18
9.46
33.86% 89.80%
2.4B
6.6B
-4.32% -4.67%
12.53
0.37
2.78% -0.99%
SMALL-CAP
1.4B
3.2B
8.08% -63.68%
-2.01
0.42
7.73% -1066.14%
355.5M
163.3M
8.18% -20.52%
-14.47
2.18
7.14% -56.09%
218.8M
329.5M
3.17% -52.24%
-15.5
0.66
0.49% 64.22%
72.8M
50.3M
4.50% -30.54%
-4.8
1.45
3.23% 20.81%
4.5M
3.7M
-15.66% 215.09%
-0.37
1.2
5.77% 8.23%

Akoya Biosciences, Inc. News

Latest updates
Yahoo Canada Finance22 hours ago
Simply Wall St28 Feb 202410:44 am
Yahoo Finance24 Feb 202412:57 pm
Marketscreener.com08 Jan 202408:00 am

Akoya Biosciences, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q1
Revenue7.2%25,215,00023,521,00021,410,00021,219,00018,852,00017,894,00016,894,00016,158,00013,476,00013,071,00012,212,00012,908,0009,954,0008,560,00011,021,000
Cost Of Revenue-12.9%9,939,00011,405,0009,117,0009,173,0007,945,0007,553,0006,798,0005,932,0005,023,0004,937,0004,807,0005,000,0003,920,0003,290,0004,325,000
Gross Profit26.1%15,276,00012,116,00012,293,00012,046,00010,907,00010,341,00010,096,00010,226,0008,453,0008,134,0007,405,0007,908,0006,034,0005,270,0006,696,000
Operating Expenses-14.4%26,827,00031,358,00029,729,00029,637,00027,560,00026,649,00025,650,00027,006,00019,192,00014,512,00012,806,00011,057,0009,701,0009,102,0008,059,000
  S&GA Expenses-16.3%19,017,00022,708,00021,758,00020,948,00019,922,00020,590,00018,193,00019,046,00013,725,00010,066,0008,179,0006,816,0005,712,0005,105,0006,349,000
  R&D Expenses-17.5%5,173,0006,273,0005,773,0006,433,0005,466,0005,598,0005,714,0005,563,0003,999,0002,947,0003,192,0002,532,0002,279,0002,420,0002,372,000
EBITDA Margin16.7%-0.62-0.74-0.77-0.81-0.86-0.85-0.73-0.65-0.46-0.35-0.37-0.25---
Interest Expenses3.2%1,973,0001,912,0001,793,0001,288,000899,000652,000638,000726,000652,000652,000638,000871,000464,000454,000457,000
Income Taxes-16.7%15,00018,00029,000-26,00021,000106,00022,000-117,000-11,000-6,000-6,000-26,000-9,00039,00038,000
Earnings Before Taxes37.9%-12,901,000-20,785,000-18,773,000-18,901,000-17,851,000-17,389,000-16,377,000-17,790,000-11,628,000-5,569,000-8,088,000-5,720,000-4,293,000-4,546,000-2,105,000
EBT Margin13.0%-0.78-0.90-0.92-0.94-0.99-0.98-0.86-0.78-0.60-0.49-0.52-0.39---
Net Income37.9%-12,916,000-20,803,000-18,802,000-18,875,000-17,872,000-17,495,000-16,399,000-17,673,000-11,617,000-5,563,000-8,082,000-5,694,000-4,284,000-4,585,000-2,143,000
Net Income Margin13.0%-0.78-0.90-0.92-0.94-0.99-0.98-0.86-0.78-0.60-0.49-0.52-0.39---
Free Cashflow-10.3%-14,585,000-13,227,000-20,562,000-10,876,000-15,960,000-14,950,000-19,070,000-7,219,000-15,270,000-13,362,000-5,311,000-2,634,000-2,602,000--
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q4
Assets-6.2%17718915417617618418719119520674.0078.00
  Current Assets-7.3%11712692.0011211212012614114615724.0029.00
    Cash Equivalents-15.8%79.0093.0060.0074.0052.0047.0094.0011312013612.0018.00
  Inventory16.2%19.0016.0015.0014.0013.0013.0011.009.006.007.005.004.00
  Net PPE-2.7%11.0011.0010.0010.0010.009.008.007.006.006.006.006.00
  Goodwill0%18.0018.0018.0018.0018.0018.0018.0018.0018.0018.0018.0018.00
Liabilities-1.5%11511711211710193.0081.0070.0058.0059.0064.0060.00
  Current Liabilities-5.0%36.0037.0033.0037.0032.0034.0032.0028.0017.0018.0021.0017.00
  Long Term Debt0.3%64.0064.0063.0063.0053.0043.0033.0032.0032.0032.0033.0033.00
    LT Debt, Non Current0.3%64.0064.0063.0063.0053.0043.0033.0032.0032.0032.0033.0033.00
Shareholder's Equity-13.8%62.0072.0042.0059.0075.0091.001071211371480.000.00
  Retained Earnings-6.3%-219-206-185-166-147-130-112-96.11-78.43-66.82-61.25-52.28
  Additional Paid-In Capital1.1%281278228225223221219217216215--
Shares Outstanding0%49.0049.0038.0038.0038.0038.0037.0037.0023.0030.003.003.00
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q1
Cashflow From Operations-16.5%-13,753-11,804-19,758-10,007-12,171-13,386-17,932-5,854-13,395-12,415-4,404-2,147-1,740-1,999-957
  Share Based Compensation9.8%2,8782,6202,3752,1202,0441,7211,5451,4111,1581,21625454.0060.0051.00312
Cashflow From Investing41.5%-832-1,4236,19622,1317,266-42,338-1,138-1,365-1,875-947-9079,653-902-588-1,435
Cashflow From Financing-100.3%-14146,327-41910,2709,8608,667-71.00149-44.00136,934-4.005,68740.002,419-2,660

AKYA Income Statement

2023-09-30
CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($)
$ in Thousands
3 Months Ended9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Revenue$ 25,215$ 18,852$ 70,146$ 53,640
Cost of goods sold9,9397,94530,46122,296
Gross profit15,27610,90739,68531,344
Operating expenses:    
Selling, general and administrative19,01719,92263,48358,705
Research and development5,1735,46617,21916,778
Change in fair value of contingent consideration2623571,019(599)
Depreciation and amortization2,3751,8156,1934,975
Total operating expenses26,82727,56087,91479,859
Loss from operations(11,551)(16,653)(48,229)(48,515)
Other income (expense):    
Interest expense(2,239)(1,109)(6,468)(2,707)
Interest income1,0741362,576212
Other expense, net(185)(225)(338)(607)
Loss before provision for income taxes(12,901)(17,851)(52,459)(51,617)
Provision for income taxes(15)(21)(62)(149)
Net loss$ (12,916)$ (17,872)$ (52,521)$ (51,766)
Net loss per share attributable to common stockholders, basic$ (0.26)$ (0.47)$ (1.23)$ (1.37)
Net loss per share attributable to common stockholders, diluted$ (0.51)$ (0.47)$ (1.00)$ (0.90)
Weighted-average shares outstanding, basic48,975,43237,900,82142,686,06537,660,814
Weighted-average shares outstanding, diluted40,639,71437,612,33139,489,26137,538,821
Product    
Revenue$ 18,048$ 14,438$ 50,719$ 41,942
Cost of goods sold6,2085,45519,74714,733
Service and other    
Revenue7,1674,41419,42711,698
Cost of goods sold$ 3,731$ 2,490$ 10,714$ 7,563

AKYA Balance Sheet

2023-09-30
CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Current assets  
Cash and cash equivalents$ 78,595$ 74,229
Marketable securities 6,989
Accounts receivable, net16,0969,729
Inventories, net18,75214,486
Prepaid expenses and other current assets3,5056,764
Total current assets116,948112,197
Property and equipment, net10,84310,174
Restricted cash330303
Demo inventory, net1,3052,084
Intangible assets, net18,12320,048
Goodwill18,26218,262
Operating lease right of use assets, net9,00310,785
Financing lease right of use assets, net1,7761,490
Other assets654688
Total assets177,244176,031
Current liabilities  
Accounts payable11,89010,628
Accrued expenses and other current liabilities13,19416,519
Current portion of operating lease liabilities2,7903,009
Current portion of financing lease liabilities799620
Deferred revenue6,8506,279
Total current liabilities35,52337,055
Deferred revenue, net of current portion2,7822,114
Long-term debt, net of debt discount63,81863,277
Deferred tax liability, net8787
Operating lease liabilities, net of current portion6,7528,203
Financing lease liabilities, net of current portion914675
Contingent consideration liability (Note 4), net of current portion5,2556,039
Other liabilities140 
Total liabilities115,271117,450
Stockholders' equity  
Preferred Stock, $0.00001 par value; 10,000,000 shares authorized; 0 shares issued and outstanding at September 30, 2023 and December 31, 2022, respectively
Common Stock, $0.00001 par value; 500,000,000 shares authorized at September 30, 2023 and December 31, 2022; 49,062,360 and 38,288,188 shares issued and outstanding at September 30, 2023 and December 31, 2022, respectively22
Additional paid in capital281,240225,333
Accumulated deficit(219,269)(166,748)
Accumulated other comprehensive loss (6)
Total stockholders' equity61,97358,581
Total liabilities and stockholders' equity$ 177,244$ 176,031
AKYA
Akoya Biosciences, Inc., a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research in North America, the Asia Pacific, Europe, the Middle East, and Africa. The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImager platform that enables researchers to visualize, analyze, quantify, and phenotype cells in situ, in fresh frozen or FFPE tissue sections, and tissue microarrays utilizing an automated and high-throughput workflow. It also provides PhenoCycler and PhenoImager reagents; and biopharma services. In addition, the company offers analysis software partnerships ecosystem; inForm Tissue, an automated image analysis software package for accurately visualizing and quantifying biomarkers in tissue sections; Phenoptr, which provides functions that consolidate and analyze output tables created by inForm software; and phenoptrReports, a software that generates shareable reports and visualizations based on the phenoptr output in an intuitive front-end GUI. The company was incorporated in 2015 and is headquartered in Marlborough, Massachusetts.
 CEO
 WEBSITEwww.akoyabio.com
 EMPLOYEES369

Akoya Biosciences, Inc. Frequently Asked Questions


What is the ticker symbol for Akoya Biosciences, Inc.? What does AKYA stand for in stocks?

AKYA is the stock ticker symbol of Akoya Biosciences, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Akoya Biosciences, Inc. (AKYA)?

As of Thu Feb 29 2024, market cap of Akoya Biosciences, Inc. is 280.22 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of AKYA stock?

You can check AKYA's fair value in chart for subscribers.

What is the fair value of AKYA stock?

You can check AKYA's fair value in chart for subscribers. The fair value of Akoya Biosciences, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Akoya Biosciences, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for AKYA so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Akoya Biosciences, Inc. a good stock to buy?

The fair value guage provides a quick view whether AKYA is over valued or under valued. Whether Akoya Biosciences, Inc. is cheap or expensive depends on the assumptions which impact Akoya Biosciences, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for AKYA.

What is Akoya Biosciences, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Feb 29 2024, AKYA's PE ratio (Price to Earnings) is -3.92 and Price to Sales (PS) ratio is 3.07. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. AKYA PE ratio will change depending on the future growth rate expectations of investors.